Figure 8.
Metabolic activation and antiviral activity of cyclic monophosphate prodrugs of modified adenosines
aFrom reference [57]. bEffective concentration of compound required to reduce HCV replication by 50% (EC50). cConcentration of inhibitor reducing cell viability by 50% (CC50). dFrom reference [48]. eParent nucleoside (Nuc). Oi-Pr, O-isopropyl; t-Bu, tert-butyl.